ITGAX and metabolic dysfunction-associated steatohepatitis: A study also showed that ASTN treatment increased M2 macrophages with markers such as CD206 and IL-10, while it decreased M1 macrophages with markers such as CD11c and CCR2 in a high-fat, cholesterol, and cholate diet-induced mouse NASH model [37].